Comparative Pharmacology
Head-to-head clinical analysis: ABACAVIR LAMIVUDINE versus ABACAVIR SULFATE LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABACAVIR LAMIVUDINE versus ABACAVIR SULFATE LAMIVUDINE.
ABACAVIR; LAMIVUDINE vs ABACAVIR SULFATE; LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Abacavir is a carbocyclic synthetic nucleoside analogue (guanosine analogue) that is phosphorylated intracellularly to carbovir triphosphate, which competes with deoxyguanosine triphosphate for incorporation into viral DNA by HIV reverse transcriptase, leading to chain termination. Lamivudine is a synthetic nucleoside analogue (cytosine analogue) that is phosphorylated intracellularly to lamivudine triphosphate, which competes with deoxycytidine triphosphate for incorporation into viral DNA by HIV reverse transcriptase, causing chain termination.
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that, after intracellular phosphorylation to carbovir triphosphate, competes with natural deoxyguanosine triphosphate for incorporation into viral DNA, causing chain termination. Lamivudine is an NRTI that, after phosphorylation to lamivudine triphosphate, inhibits HIV-1 reverse transcriptase via incorporation into viral DNA, resulting in chain termination.
One tablet (abacavir 600 mg/lamivudine 300 mg) orally once daily with or without food. Can be used in combination with other antiretrovirals.
One tablet (abacavir 600 mg/lamivudine 300 mg) once daily, in combination with other antiretrovirals.
None Documented
None Documented
Abacavir: 1.5 hr (single dose) to 2 hr (steady state), clinically short requiring twice-daily dosing. Lamivudine: 5-7 hr (adults), extended in renal impairment (up to 20 hr with CrCl <50 mL/min).
Abacavir: 1.5 h; Lamivudine: 5-7 h (intracellular 10-15 h). Clinical context: Both support twice-daily dosing; lamivudine's longer intracellular half-life allows once-daily dosing.
Abacavir: 83% renal (1.2% unchanged, rest as metabolites), 16% fecal. Lamivudine: ~70% renal (mostly unchanged via tubular secretion), ~5% fecal.
Renal: Abacavir ~83% (metabolites), Lamivudine ~70% (unchanged). Fecal: Abacavir ~16%, Lamivudine minimal. Biliary: negligible.
Category A/B
Category A/B
NRTI
NRTI